VYNE - VYNE Therapeutics surged ~39% since FDA approval for label update

VYNE Therapeutics (VYNE) has gained ~38.9% since the company announced last week that the FDA has authorized the inclusion of new information in the product label for AMZEEQ® (minocycline) topical foam, 4%.The label update refers to a low propensity of P. acnes strains to develop resistance to minocycline, the active ingredient in AMZEEQ.Noting that the risk of antimicrobial resistance is a primary concern among dermatologists and other prescribers of antibiotics in general, David Domzalski, CEO of VYNE said, the new FDA approval “will support prescribers in making informed decisions on both their choice of antibiotic and administration route when selecting a treatment for acne.”In October 2019, the FDA approved AMZEEQ (minocycline) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients aged nine years and above.

For further details see:

VYNE Therapeutics surged ~39% since FDA approval for label update